TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20467623
Drug: Early loading
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loading of dental implants (6 weeks)
Study: 12580841
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% 20 mL injected into the uterus, fallopian tubes, and pelvis
Study: 12580841
Drug: Placebo normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo normal saline 20 mL injected into the uterus, fallopian tubes, and pelvis
Study: 11113041
Drug: abciximab with
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: abciximab with standard-dose weight-adjusted heparin
Study: 11113041
Drug: placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo with standard-dose weight-adjusted heparin
Study: 1418046
Drug: 1% flutrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% flutrimazole skin cream
Study: 1418046
Drug: 2% flutrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% flutrimazole skin cream
Study: 1418046
Drug: 1% clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clotrimazole commercial skin cream
Study: 3856293
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg PGE2
Study: 3856293
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg PGE2
Study: 27348915
Drug: Needle-pricking therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-pricking therapy at Guanyuan (CV 4) and bilateral sacral plexus nerve, lumbar 1 nerve and greater occipital nerve stimulating points, once a week for 9 weeks
Study: 27348915
Drug: Midodrine tablets
Normalized name: midodrine Oral Tablet
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Midodrine tablets prescribed orally, three times a day for 9 weeks
Study: 24721240
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine Liuweiwuling tablets in combination with entecavir
Study: 1283552
Drug: Nurse-administered intermittent
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered intermittent intramuscular (IM) injections of morphine
Study: 3004550
Drug: Antituberculous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antituberculous chemotherapy (2-week course)
Study: 3004550
Drug: Antituberculous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antituberculous chemotherapy including rifampicin
Study: 3004550
Drug: Antituberculous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antituberculous chemotherapy without rifampicin
Study: 31295009
Drug: Xinmailong injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinmailong injection (100 mg/2 mL, intravenous drip infusion)
Study: 31295009
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus XI
Study: 22702508
Drug: SCH527123, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH527123, 30 mg daily PO
Study: 15735456
Drug: Oral fluid
Normalized name: cascara sagrada ORAL FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluid test with standard counseling
Study: 3294284
Drug: Intravenous dextro‐amphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dextro‐amphetamine
Study: 29569470
Drug: In-hospital consultation
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital consultation using the home and community environment assessment and the Lawton Instrumental Activities of Daily Living assessment
Study: 20356395
Drug: Conventional therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapeutic exercise classes (12 weekly sessions)
Study: 18344733
Drug: Olanzapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (mean dose 11.3 mg)
Study: 18344733
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean dose 3.0 mg)
Study: 16546280
Drug: IH636 grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: IH636 grape seed proanthocyanidin extract (GSPE) 100 mg three times a day orally for 6 months
Study: 10714421
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (rehabilitation program consisting of exercise and education twice a week for 8 weeks)
Study: 8330466
Drug: CGS-12970 (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS-12970 (100, 200, 300, or 400 mg twice a day)
Study: 27418249
Drug: Intermittent occlusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent occlusion therapy (IO therapy) using liquid crystal glasses (Amblyz), 4 hours per day, set at 30‐second opaque/transparent intervals (occluded 50% of wear time)
Study: 27418249
Drug: Continuous occlusion
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous occlusion therapy using traditional adhesive patches, 2 hours per day (occluded 100% of wear time)
Study: 15930204
Drug: Immediate antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antibiotics (ABX; amoxicillin plus symptom medication)
Study: 15930204
Drug: Watchful waiting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watchful waiting (WW; symptom medication only)
Study: 15930204
Drug: Immediate antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antibiotics (ABX)
Study: 10227568
Drug: Acarbose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (50 mg t.d.s. for the first 2 weeks, then 100 mg t.d.s. for the subsequent weeks)
Study: 1859010
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) 15 micrograms/kg
Study: 1859010
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution of fentanyl citrate (control) 15 micrograms/kg
Study: 1859010
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution of fentanyl citrate (control)
Study: 7341285
Drug: Mianserin 20
Normalized name: mianserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 20 mg tid for 3 days
Study: 7341285
Drug: Mianserin pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin pre-treatment
Study: 28865493
Drug: Infliximab 3
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 3 mg/kg from weeks 0 to 6, then 3, 6, or 10 mg/kg every 8 weeks from weeks 14 to 46
Study: 25111437
Drug: Cryolipolysis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryolipolysis treatment on larger thigh
Study: 17173586
Drug: Patients in
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in group A who underwent treatment
Study: 10715982
Drug: Perfix plug-and-patch
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfix plug-and-patch
Study: 2995279
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g dietary fibre supplements in the form of a corn‐based biscuit (Group A)
Study: 2995279
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g dietary fibre supplements as wheat bran (Group B)
Study: 19673652
Drug: Cell culture-derived
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell culture-derived influenza vaccine (CCIV)
Study: 12752139
Drug: Alefacept therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept therapy
Study: 9350389
Drug: Slow-release lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release lithium carbonate, 800 mg/day
Study: 1332985
Drug: 17 alpha-hydroxyprogesterone
Normalized name: 17 alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 alpha-hydroxyprogesterone caproate and oestradiol valerate (PC/EV) administered until the twelfth week of gestation
Study: 3715407
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 50 to 3900 mg daily for 1 week
Study: 3715407
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 100 mg daily for 1 week
Study: 3715407
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) higher doses (above 100 mg)
Study: 16540864
Drug: Matched treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched treatment (manipulation, stabilization exercise, or specific exercise)
Study: 16540864
Drug: Unmatched treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmatched treatment (manipulation, stabilization exercise, or specific exercise)
Study: 12669236
Drug: Carboplatin and
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin and prolonged oral etoposide (group 1; n=58)
Study: 12669236
Drug: Carboplatin and
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin and prolonged oral etoposide (group 1; n=84)
Study: 12669236
Drug: Carboplatin and
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin and high-dose intravenous etoposide (group 2; n=84)
Study: 24424109
Drug: Generic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic preparation of 4.2 mg fentanyl
Study: 24424109
Drug: Durogesic patch
Normalized name: Dologesic
DrugBank: Phenyltoloxamine (DB11160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Durogesic patch of 4.2 mg fentanyl
Study: 22964716
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of UDCA (1 g/day during 3 weeks before surgery) and RIFA (600 mg/day during 1 week before surgery)
Study: 20026112
Drug: G-CSF deficiency
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF deficiency
Study: 12425756
Drug: ddAT (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ddAT (doxorubicin 50 mg/m2 and docetaxel 75 mg/m2) with prophylactic granulocyte colony-stimulating factor support (5 micro g/kg days 5-10)
Study: 30608308
Drug: Constraint‐induced movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint‐induced movement therapy (CI therapy)
Study: 30608308
Drug: CI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI therapy
Study: 23378458
Drug: Wellmune (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wellmune (250 mg daily for 12 weeks)
Study: 23378458
Drug: Placebo (self-administered)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (self-administered)
Study: 19765608
Drug: Boy Scout
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boy Scout Five‐A‐Day Badge program (9-week program with 30 min weekly troop time and 25 min weekly Internet programming)
Study: 17530530
Drug: Zileuton controlled
Normalized name: Zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zileuton controlled release (CR) 1,200 mg BID
Study: 14998852
Drug: MMC +
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC + GEM (Mitomycin C 8 mg/m2 on day 1 + Gemcitabine 2000 mg/m2 on days 1 and 15 every 4 weeks)
Study: 14998852
Drug: MMC +
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC + CAPE (Mitomycin C 8 mg/m2 on day 1 + Capecitabine 2000 mg/m2/day on days 1-14 every 4 weeks)
Study: 11514369
Drug: Intravenous gamma
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gamma globulin therapy
Study: 9700472
Drug: Alendronate 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 2.5 mg/day (L)
Study: 9700472
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg/day (H)
Study: 8077368
Drug: beta-endorphin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-endorphin (0.5 mg/h)
Study: 8077368
Drug: naloxone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone (5 mg in 5 min)
Study: 30773731
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg three times a day orally for 2 weeks
Study: 30451560
Drug: Peer support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer support group intervention (8 weekly sessions of 1.5 hours each)
Study: 16772442
Drug: Dual fortified
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual fortified salt (DFS) with 3 mg Fe/g salt as ground FePP
Study: 11520368
Drug: Weekly regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly regimen (paclitaxel 60 mg/m2, carboplatin AUC 2)
Study: 11520368
Drug: Monthly regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly regimen (paclitaxel 175 mg/m2, carboplatin AUC 6)
Study: 11520368
Drug: Weekly regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly regimen
Study: 9777130
Drug: Reteplase administration
Normalized name: reteplase
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reteplase administration
Study: 9777130
Drug: Double bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double bolus alteplase administration
Study: 7890014
Drug: Probucol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (500 mg bd)
Study: 7890014
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 IU daily)
Study: 27230863
Drug: 12-week Internet
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week Internet intervention (Deprexis) adjunctive to usual care
Study: 23189301
Drug: Submerged dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submerged dental implants in organ transplant patients
Study: 23189301
Drug: Submerged dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submerged dental implants in control patients
Study: 10931390
Drug: G-CSF treatment
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF treatment combined with HAART
Study: 2942599
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms of HB‐VAX vaccine
Study: 2942599
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms of HB‐VAX vaccine
Study: 31705154
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) under current local resources
Study: 31705154
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) under assumed ideal conditions
Study: 29555019
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with precise treatment expectations
Study: 23771450
Drug: Adherence counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence counseling and twice weekly short message reminders for four months
Study: 11034942
Drug: BQ‐123 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ‐123 (6 micromol/L over 20 minutes)
Study: 18349194
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of liquid sevoflurane to achieve a target end-tidal concentration of 1%
Study: 18349194
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of liquid sevoflurane to achieve a target end-tidal concentration of 1.5%
Study: 18349194
Drug: Infusion scheme
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion scheme to increase target concentration by 0.3%
Study: 18349194
Drug: Infusion scheme
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion scheme to decrease target concentration by 0.3%
Study: 14640465
Drug: Simvastatin (20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20-80 mg)
Study: 9413107
Drug: Two primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two primary doses of DTaP
Study: 9413107
Drug: Three primary
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three primary doses of DTaP
Study: 9413107
Drug: Two primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two primary doses of DTaP followed by a booster
Study: 9413107
Drug: Three primary
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three primary doses of DTaP followed by a booster
Study: 3758146
Drug: DHE 1
Normalized name: Dihydroergotamine
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DHE 1 mg intranasally
Study: 3758146
Drug: DHE 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHE 0.5 mg intramuscularly
Study: 21256606
Drug: Adenosine 50
Normalized name: adenosine 50 mcg/mL-NaCl 0.9% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine 50 μg (n=54)
Study: 21256606
Drug: Nicorandil 4
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 4 mg (n=54)
Study: 21256606
Drug: Adenosine-nicorandil combination
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine-nicorandil combination (n=50)
Study: 14531555
Drug: 5-aminolevulinic acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminolevulinic acid (5-ALA) administration for fluorescence-guided resections
Study: 8613538
Drug: DHA-rich oil
Normalized name: Ulkenia DHA oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich oil capsules (1.5-1.8 grams DHA/day)
Study: 10419086
Drug: Control oil
Normalized name: SALICYLIC ACID 29.2 mg TOPICAL LIQUID [Acne Control oil-free Cleansing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control oil capsules (97% soybean oil + 3% fish oil)
Study: 3882681
Drug: Fluoxetine 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 75 mg
Study: 29368635
Drug: Strict glycaemic
Normalized name: Euphrasia stricta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict glycaemic control (4-7 mmol/L; 72-126 mg/dl)
Study: 29368635
Drug: Conventional glycaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glycaemic control (<10 mmol/L; 180 mg/dl)
Study: 18413554
Drug: Simvastatin, 20
Normalized name: Simvastatin, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin, 20 mg
Study: 10601051
Drug: Intraduodenal long
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal long chain triglyceride (LCT) infusion
Study: 10601051
Drug: Intraduodenal medium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal medium chain triglyceride (MCT) infusion
Study: 3516395
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (3 g/m2 every 12 hours for 6 days)
Study: 3516395
Drug: Amsacrine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amsacrine (75 mg/m2 daily for 7 days)
Study: 23567070
Drug: Paricalcitol treatment
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paricalcitol treatment
Study: 16887443
Drug: Prednisone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (1 mg/kg/day for 2 weeks, with weaning over the subsequent 2 weeks)
Study: 9024171
Drug: Acetaminophen coadministered
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen coadministered with isoniazid (8 am dose)
Study: 9024171
Drug: Acetaminophen given
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen given 12 hours after isoniazid dose
Study: 9024171
Drug: Acetaminophen with
Normalized name: acetaminophen with codeine ORAL ELIXIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen with isoniazid for fast acetylators
Study: 9024171
Drug: Acetaminophen with
Normalized name: acetaminophen with codeine ORAL ELIXIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen with isoniazid for slow acetylators
Study: 8155010
Drug: Aspirin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (30 or 283 mg/d)
Study: 30282670
Drug: Etanercept (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (50 mg/week for 24 weeks, then 25 mg/week)
Study: 18196524
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg simvastatin (SV) tablet formulation
Study: 17075122
Drug: Bortezomib 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.3 mg/m2 plus docetaxel 75 mg/m2 (arm B)
Study: 8612412
Drug: Propofol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.75 mg/kg)
Study: 8612412
Drug: Propofol (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.35 mg/kg)
Study: 1329937
Drug: Variable oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable oestrogen dosage regimen
Study: 1329937
Drug: Fixed 1
Normalized name: cariprazine
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed 1 mg oestrogen dosage regimen
Study: 1329937
Drug: Fixed 2
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed 2 mg oestrogen dosage regimen
Study: 1329937
Drug: Fixed 4
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed 4 mg oestrogen dosage regimen